Theravance to Present at the Leerink Swann Global Healthcare Conference 2013

Theravance to Present at the Leerink Swann Global Healthcare Conference 2013 
SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/31/13 --  Theravance,
Inc. (NASDAQ: THRX) announced today that that Michael W. Aguiar,
Theravance's Senior Vice President and Chief Financial Officer, is
scheduled to present at the Leerink Swann Healthcare Conference 2013
on Thursday, February 14, 2013, at 8:30 a.m. EST. The conference will
be held from February 13-14, 2013 at the Waldorf Astoria in New York
City, New York. 
The presentation will be webcast live and can be reached from
Theravance's web site at Listeners are encouraged
to visit the site at least 15 minutes prior to the scheduled
presentation to register, download and install any necessary audio
About Theravance 
Theravance is a biopharmaceutical company with a pipeline of
internally discovered product candidates and strategic collaborations
with pharmaceutical companies. Theravance is focused on the
discovery, development and commercialization of small molecule
medicines across a number of therapeutic areas including respiratory
disease, bacterial infections, and central nervous system (CNS)/pain.
Theravance's key programs include: RELVAR(TM) or BREO(TM) (FF/VI),
ANORO(TM) (UMEC/VI) and MABA (Bifunctional Muscarinic
Antagonist-Beta2 Agonist), each partnered with GlaxoSmithKline plc,
and its oral Peripheral Mu Opioid Receptor Antagonist program. By
leveraging its proprietary insight of multivalency to drug discovery,
Theravance is pursuing a best-in-class strategy designed to discover
superior medicines in areas of significant unmet medical need. For
more information, please visit Theravance's web site at 
THERAVANCE(R), the Theravance logo, and MEDICINES THAT MAKE A
DIFFERENCE(R) are registered trademarks of Theravance, Inc.  
investigational medicines and are not currently approved anywhere in
the world. RELVAR(TM), BREO(TM) and ANORA(TM) are trademarks of the
GlaxoSmithKline group of companies. The use of these brand names has
not yet been approved by any regulatory authority. 
VIBATIV(R) is a registered trademark of Theravance, Inc. 
Theravance's presentation will contain certain "forward-looking"
ents as that term is defined in the Private Securities
Litigation Reform Act of 1995 regarding, among other things,
statements relating to goals, plans, objectives and future events.
Theravance intends such forward-looking statements to be covered by
the safe harbor provisions for forward-looking statements contained
in Section 21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995. Examples of such statements
include statements relating to the status and timing of clinical
studies, data analysis and communication of results, statements
regarding the potential benefits and mechanisms of action of drug
candidates, statements concerning the timing of seeking regulatory
approval of our product candidates (including with respect to
VIBATIV(R) statements regarding any expectation that we will be able
to respond fully or adequately to FDA's requests using currently
existing clinical data and any expectation that the FDA will approve
the VIBATIV(R) nosocomial pneumonia NDA on the basis of existing
preclinical and clinical data or at all), statements concerning the
enabling capabilities of Theravance's approach to drug discovery and
its proprietary insights, statements concerning expectations for the
discovery, development and commercialization of our product
candidates and projections of revenue, expenses and other financial
items. These statements are based on the c
urrent estimates and
assumptions of the management of Theravance as of the date of the
presentation and are subject to risks, uncertainties, changes in
circumstances, assumptions and other factors that may cause the
actual results of Theravance to be materially different from those
reflected in its forward-looking statements. Important factors that
could cause actual results to differ materially from those indicated
by such forward-looking statements include, among others, risks
related to delays or difficulties in commencing or completing
clinical and non-clinical studies, the potential that results of
clinical or non-clinical studies indicate product candidates are
unsafe or ineffective, our dependence on third parties in the conduct
of our clinical studies, delays or failure to achieve regulatory
approvals for product candidates, risks of relying on third-party
manufacturers for the supply of our product and product candidates
and risks of collaborating with third parties to discover, develop
and commercialize products. These and other risks are described in
greater detail under the heading "Risk Factors" contained in
Theravance's Quarterly Report on Form 10-Q filed with the Securities
and Exchange Commission (SEC) on October 31, 2012 and in Theravance's
prospectus supplement filed with the SEC on January 18, 2013 pursuant
to Rule 424(b)(5). Given these uncertainties, you should not place
undue reliance on these forward-looking statements. Theravance
assumes no obligation to update its forward-looking statements. 
Contact Information: 
Michael W. Aguiar 
Senior Vice President and Chief Financial Officer
Press spacebar to pause and continue. Press esc to stop.